AU2004270275B2 - Lentivirus vector-based approaches for generating an immune response to HIV humans - Google Patents

Lentivirus vector-based approaches for generating an immune response to HIV humans Download PDF

Info

Publication number
AU2004270275B2
AU2004270275B2 AU2004270275A AU2004270275A AU2004270275B2 AU 2004270275 B2 AU2004270275 B2 AU 2004270275B2 AU 2004270275 A AU2004270275 A AU 2004270275A AU 2004270275 A AU2004270275 A AU 2004270275A AU 2004270275 B2 AU2004270275 B2 AU 2004270275B2
Authority
AU
Australia
Prior art keywords
vector
hiv
vectors
immune response
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004270275A
Other languages
English (en)
Other versions
AU2004270275A1 (en
Inventor
Boro Dropulic
Xiaobin Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VirxSys Corp
Original Assignee
VirxSys Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VirxSys Corp filed Critical VirxSys Corp
Publication of AU2004270275A1 publication Critical patent/AU2004270275A1/en
Application granted granted Critical
Publication of AU2004270275B2 publication Critical patent/AU2004270275B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004270275A 2003-09-09 2004-09-09 Lentivirus vector-based approaches for generating an immune response to HIV humans Ceased AU2004270275B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50166503P 2003-09-09 2003-09-09
US60/501,665 2003-09-09
PCT/US2004/029492 WO2005023313A1 (en) 2003-09-09 2004-09-09 Lentivirus vector-based approaches for generating an immune response to hiv humans

Publications (2)

Publication Number Publication Date
AU2004270275A1 AU2004270275A1 (en) 2005-03-17
AU2004270275B2 true AU2004270275B2 (en) 2010-02-18

Family

ID=34273064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004270275A Ceased AU2004270275B2 (en) 2003-09-09 2004-09-09 Lentivirus vector-based approaches for generating an immune response to HIV humans

Country Status (6)

Country Link
US (3) US20050196381A1 (https=)
EP (2) EP1677832A1 (https=)
JP (1) JP2007505130A (https=)
AU (1) AU2004270275B2 (https=)
CA (1) CA2537953A1 (https=)
WO (1) WO2005023313A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090217399A1 (en) * 2006-03-17 2009-08-27 Massachusetts Institute Of Technology Lentiviral Vectors That Provide Improved Expression And Reduced Variegation After Transgenesis
WO2008005929A2 (en) * 2006-06-30 2008-01-10 New York University Recombinant hiv-1 gp120 immunogen with three different v3 loops from viruses of different clades
RS56844B1 (sr) 2007-12-11 2018-04-30 Univ North Carolina Chapel Hill Retrovirusni vektori sa modifikovanim polipurinskim nizom
JP2012520084A (ja) * 2009-03-13 2012-09-06 レンチゲン コーポレイション 非組み込み型レトロウイルスベクターワクチン
US20130302368A1 (en) * 2011-01-27 2013-11-14 Boro Dropulic Advanced Prime and Boost Vaccine
US9632087B2 (en) 2013-09-10 2017-04-25 MockV Solutions Methods for evaluating viral clearance from a biopharmaceutical solution employing mock viral particles
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
AU2022377374A1 (en) 2021-10-25 2024-05-02 Genvivo, Inc. Compositions and methods for therapeutic or vaccine delivery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012622A1 (en) * 1995-10-06 1997-04-10 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO2002024897A2 (en) * 2000-09-22 2002-03-28 Virxsys Conditionally replicating viral vectors and their use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063652A1 (en) * 1988-03-21 2004-04-01 Jolly Douglas J. Combination gene delivery vehicles
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
DE69128898T2 (de) * 1990-08-15 1998-05-28 Therion Biolog Corp Selbstständig zusammenfügende replikationsdefekte hybride viruspartikel
US5866137A (en) * 1990-10-12 1999-02-02 Benjamin Rovinski Self-assembled, non-infectious, non-replicating; immunogenic retrovirus-like particles comprising modified HIV genomes devoid of long terminal repeats and chimeric envelope glycoproteins
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
FR2747046B1 (fr) * 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
JP2001501620A (ja) * 1996-10-04 2001-02-06 デメジェン インコーポレイテッド 免疫不全ウイルス感染の治療方法
US6248721B1 (en) * 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
JP2001510053A (ja) * 1997-07-18 2001-07-31 カイロン コーポレイション レンチウイルスベクター
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
CA2331599C (en) * 1998-05-12 2005-11-29 Genecure Llc Replication defective hiv vaccine
EP1059357A1 (en) * 1999-06-09 2000-12-13 Universite Pierre Et Marie Curie Paris Vi Replicating or semi-replicating retroviral constructs, preparation and uses for gene delivery
AU2001265219A1 (en) * 2000-05-31 2001-12-11 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US6712612B1 (en) * 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012622A1 (en) * 1995-10-06 1997-04-10 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO2002024897A2 (en) * 2000-09-22 2002-03-28 Virxsys Conditionally replicating viral vectors and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Demaison C. et al., Human Gene Therapy, 2002, Vol. 13, No. 7, pages 803-813 *
Mangeot P.-E. et al., Journal of Virology, 2000, Vol. 74, No. 18, pages 8307-8315 *

Also Published As

Publication number Publication date
EP1677832A1 (en) 2006-07-12
US20050196381A1 (en) 2005-09-08
US20150030627A1 (en) 2015-01-29
CA2537953A1 (en) 2005-03-17
EP2055316A1 (en) 2009-05-06
US20060281128A1 (en) 2006-12-14
AU2004270275A1 (en) 2005-03-17
WO2005023313A1 (en) 2005-03-17
JP2007505130A (ja) 2007-03-08

Similar Documents

Publication Publication Date Title
JP6480028B2 (ja) レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用
US20150030627A1 (en) Trans-complementing, replication deficient lentiviral vectors and methods for making and using them
KR20090034297A (ko) 인플루엔자에 대한 항바이러스제 및 백신
Schell et al. Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen
US11400149B2 (en) Ebola virus and Marburg virus glycoprotein mucin-like domain replacement expression system used as new vaccine approaches
RU2301260C2 (ru) Вирусные векторы с зависимой от условий репликацией и их применение
DK2020444T3 (en) DEFECTIVE NON-INTEGRATIVE LENTIVIRAL TRANSMISSION VECTORS FOR VACCINES
US20040033595A1 (en) Conditionally replicating vectors for inhibiting viral infections
JP2007505130A5 (https=)
EP1255849A2 (en) Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses
US9566329B2 (en) Live, attenuated rubella vector to express vaccine antigens
WO2004039945A2 (en) Preventive and therapeutic aids vaccines
WO2017088053A1 (en) Dual-action vaccines (dav) to prevent hiv and ebola virus infections
Jia et al. Single-cycle SIV: a novel AIDS vaccine approach
AU2001293075B2 (en) Conditionally replicating viral vectors and their use
McGettigan et al. HIV-1 vaccines: the search continues
McKenna Characterization and immunogenicity of recombinant rhabdoviral vaccine vectors expressing HIV-1 and SIV envelope proteins
Malm Assessing the Immunogenicity of Gtu-based Hiv-1 Multigene Dna Vaccines in Murine Models
Wu Expression and Processing of HIV-1 GP160 with Homologous and Heterologous Signal Sequences Using a VSV Vector System
WO2002098457A2 (en) Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses
AU2001293075A1 (en) Conditionally replicating viral vectors and their use
AU2002258639A1 (en) Improved conditionally replicating vectors for inhibiting viral infections

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired